About us
The Spanish Registry of Research in Contact Dermatitis and Allergy (REIDAC) is a research project of the Spanish Group for Research in Contact Dermatitis and Skin Allergy (GEIDAC) of the AEDV that is carried out in collaboration with the Research Unit of the Foundation Fundación Piel Sana (UI).
The objective of REIDAC is to carry out epidemiological surveillance in Spain on substances that can cause contact dermatitis, so that early warnings can be made about new substances that cause contact dermatitis and monitor changes in patterns of sensitization of known allergens. The annual results of REIDAC constitute the basis for updating the Spanish standard series of contact dermatitis.
All GEIDAC members who meet the legal criteria for starting up the study participate in the project. To guarantee data privacy regulations, they are anonymised at source. The clinical data are the same and of the same categories as those established in the minimum data set of the European Surveillance System for Contact Allergies (ESSCA), which allows their export to other databases with identical categories. The structure of the database is modular, allowing prospective studies to be carried out, in which specific data is collected for a set period of time.
The registry data is shared internationally with the European Surveillance System of Contact Allergies (ESSCA) to carry out epidemiological studies jointly with other countries.
Funding
REIDAC currently has funding from the Spanish Ministry of Health through an agreement with the Spanish Agency for Medicines and Health Products (AEMPS).
The REIDAC accepts donations not conditioned by the pharmaceutical industry. The collaborating companies do not participate, nor have they participated, in the creation or management of the project. The collection, management, analysis, interpretation, publication and review of the data generated in the REIDAC is independent of the public and private funding sources of the project. REIDAC currently receives financial support from Sanofi. In the past it has received it from the companies GlaxoSmithKline and Novartis.